BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation

Ying Yan, Rebecca S. Spieker, Min Kim, Scott M. Stoeger, Kenneth H Cowan

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Germline mutations in the BRCA1 gene are associated with an increased susceptibility to the development of breast and ovarian cancers. Evidence suggests that BRCA1 protein plays a key role in mediating DNA damage-induced checkpoint responses. Several studies have shown that ectopic expression of BRCA1 in human cells can trigger cellular responses similar to those induced by DNA damage, including G2/M cell cycle arrest and apoptosis. While the effects of ectopic BRCA1 expression on the G2/M transition and apoptosis have been extensively studied, the factors that dictate the balance between these two responses remain poorly understood. We have recently shown that ectopic expression of BRCA1 in MCF-7 human breast cancer cells resulted in activation of extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) and G2/M cell cycle arrest. Furthermore, inhibition of BRCA1-induced ERK1/2 activation using mitogen-activated protein kinase kinase 1 and 2 (MEK1/2)-specific inhibitors resulted in increased apoptosis, suggesting a potential role of ERK1/2 kinases in BRCA1-mediated G2/M checkpoint response. In this study, we assessed the role of ERK1/2 kinases in the regulation of BRCA1-mediated G2/M cell cycle arrest. Results indicate that BRCA1-induced G2/M cell cycle arrest and ERK1/2 activation correlate with changes in the level and/or activity of several key regulators of the G2/M checkpoint, including activation of Chk1 and Wee1 kinases, induction of 14-3-3, and down-regulation of Cdc25C. Furthermore, inhibition of ERK1/2 kinases using MEK1/2-specific inhibitors results in a marked attenuation of the BRCA1-induced G2/M arrest. Biochemical studies established that ERK1/2 inhibition abolished the effects of BRCA1 on components of the G2/M checkpoint, including regulation of Cdc25C expression and activation of Wee1 and Chk1 kinases. These results implicate a critical role of ERK1/2 signaling in the regulation of BRCA1 function on controlling the G2/M checkpoint responses.

Original languageEnglish (US)
Pages (from-to)3285-3296
Number of pages12
JournalOncogene
Volume24
Issue number20
DOIs
StatePublished - May 5 2005

Fingerprint

G2 Phase Cell Cycle Checkpoints
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
Protein Kinases
Phosphotransferases
Apoptosis
DNA Damage
MAP Kinase Kinase 2
BRCA1 Protein
MAP Kinase Kinase 1
Breast Neoplasms
BRCA1 Gene
Myeloma Proteins
Germ-Line Mutation
Ovarian Neoplasms
Down-Regulation

Keywords

  • BRCA1
  • Cdc2
  • Cdc25C
  • Chk1
  • ERK1/2 and Wee1

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation. / Yan, Ying; Spieker, Rebecca S.; Kim, Min; Stoeger, Scott M.; Cowan, Kenneth H.

In: Oncogene, Vol. 24, No. 20, 05.05.2005, p. 3285-3296.

Research output: Contribution to journalArticle

Yan, Ying ; Spieker, Rebecca S. ; Kim, Min ; Stoeger, Scott M. ; Cowan, Kenneth H. / BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation. In: Oncogene. 2005 ; Vol. 24, No. 20. pp. 3285-3296.
@article{cde178f5d97747059a293f305868d27d,
title = "BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation",
abstract = "Germline mutations in the BRCA1 gene are associated with an increased susceptibility to the development of breast and ovarian cancers. Evidence suggests that BRCA1 protein plays a key role in mediating DNA damage-induced checkpoint responses. Several studies have shown that ectopic expression of BRCA1 in human cells can trigger cellular responses similar to those induced by DNA damage, including G2/M cell cycle arrest and apoptosis. While the effects of ectopic BRCA1 expression on the G2/M transition and apoptosis have been extensively studied, the factors that dictate the balance between these two responses remain poorly understood. We have recently shown that ectopic expression of BRCA1 in MCF-7 human breast cancer cells resulted in activation of extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) and G2/M cell cycle arrest. Furthermore, inhibition of BRCA1-induced ERK1/2 activation using mitogen-activated protein kinase kinase 1 and 2 (MEK1/2)-specific inhibitors resulted in increased apoptosis, suggesting a potential role of ERK1/2 kinases in BRCA1-mediated G2/M checkpoint response. In this study, we assessed the role of ERK1/2 kinases in the regulation of BRCA1-mediated G2/M cell cycle arrest. Results indicate that BRCA1-induced G2/M cell cycle arrest and ERK1/2 activation correlate with changes in the level and/or activity of several key regulators of the G2/M checkpoint, including activation of Chk1 and Wee1 kinases, induction of 14-3-3, and down-regulation of Cdc25C. Furthermore, inhibition of ERK1/2 kinases using MEK1/2-specific inhibitors results in a marked attenuation of the BRCA1-induced G2/M arrest. Biochemical studies established that ERK1/2 inhibition abolished the effects of BRCA1 on components of the G2/M checkpoint, including regulation of Cdc25C expression and activation of Wee1 and Chk1 kinases. These results implicate a critical role of ERK1/2 signaling in the regulation of BRCA1 function on controlling the G2/M checkpoint responses.",
keywords = "BRCA1, Cdc2, Cdc25C, Chk1, ERK1/2 and Wee1",
author = "Ying Yan and Spieker, {Rebecca S.} and Min Kim and Stoeger, {Scott M.} and Cowan, {Kenneth H}",
year = "2005",
month = "5",
day = "5",
doi = "10.1038/sj.onc.1208492",
language = "English (US)",
volume = "24",
pages = "3285--3296",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "20",

}

TY - JOUR

T1 - BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation

AU - Yan, Ying

AU - Spieker, Rebecca S.

AU - Kim, Min

AU - Stoeger, Scott M.

AU - Cowan, Kenneth H

PY - 2005/5/5

Y1 - 2005/5/5

N2 - Germline mutations in the BRCA1 gene are associated with an increased susceptibility to the development of breast and ovarian cancers. Evidence suggests that BRCA1 protein plays a key role in mediating DNA damage-induced checkpoint responses. Several studies have shown that ectopic expression of BRCA1 in human cells can trigger cellular responses similar to those induced by DNA damage, including G2/M cell cycle arrest and apoptosis. While the effects of ectopic BRCA1 expression on the G2/M transition and apoptosis have been extensively studied, the factors that dictate the balance between these two responses remain poorly understood. We have recently shown that ectopic expression of BRCA1 in MCF-7 human breast cancer cells resulted in activation of extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) and G2/M cell cycle arrest. Furthermore, inhibition of BRCA1-induced ERK1/2 activation using mitogen-activated protein kinase kinase 1 and 2 (MEK1/2)-specific inhibitors resulted in increased apoptosis, suggesting a potential role of ERK1/2 kinases in BRCA1-mediated G2/M checkpoint response. In this study, we assessed the role of ERK1/2 kinases in the regulation of BRCA1-mediated G2/M cell cycle arrest. Results indicate that BRCA1-induced G2/M cell cycle arrest and ERK1/2 activation correlate with changes in the level and/or activity of several key regulators of the G2/M checkpoint, including activation of Chk1 and Wee1 kinases, induction of 14-3-3, and down-regulation of Cdc25C. Furthermore, inhibition of ERK1/2 kinases using MEK1/2-specific inhibitors results in a marked attenuation of the BRCA1-induced G2/M arrest. Biochemical studies established that ERK1/2 inhibition abolished the effects of BRCA1 on components of the G2/M checkpoint, including regulation of Cdc25C expression and activation of Wee1 and Chk1 kinases. These results implicate a critical role of ERK1/2 signaling in the regulation of BRCA1 function on controlling the G2/M checkpoint responses.

AB - Germline mutations in the BRCA1 gene are associated with an increased susceptibility to the development of breast and ovarian cancers. Evidence suggests that BRCA1 protein plays a key role in mediating DNA damage-induced checkpoint responses. Several studies have shown that ectopic expression of BRCA1 in human cells can trigger cellular responses similar to those induced by DNA damage, including G2/M cell cycle arrest and apoptosis. While the effects of ectopic BRCA1 expression on the G2/M transition and apoptosis have been extensively studied, the factors that dictate the balance between these two responses remain poorly understood. We have recently shown that ectopic expression of BRCA1 in MCF-7 human breast cancer cells resulted in activation of extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) and G2/M cell cycle arrest. Furthermore, inhibition of BRCA1-induced ERK1/2 activation using mitogen-activated protein kinase kinase 1 and 2 (MEK1/2)-specific inhibitors resulted in increased apoptosis, suggesting a potential role of ERK1/2 kinases in BRCA1-mediated G2/M checkpoint response. In this study, we assessed the role of ERK1/2 kinases in the regulation of BRCA1-mediated G2/M cell cycle arrest. Results indicate that BRCA1-induced G2/M cell cycle arrest and ERK1/2 activation correlate with changes in the level and/or activity of several key regulators of the G2/M checkpoint, including activation of Chk1 and Wee1 kinases, induction of 14-3-3, and down-regulation of Cdc25C. Furthermore, inhibition of ERK1/2 kinases using MEK1/2-specific inhibitors results in a marked attenuation of the BRCA1-induced G2/M arrest. Biochemical studies established that ERK1/2 inhibition abolished the effects of BRCA1 on components of the G2/M checkpoint, including regulation of Cdc25C expression and activation of Wee1 and Chk1 kinases. These results implicate a critical role of ERK1/2 signaling in the regulation of BRCA1 function on controlling the G2/M checkpoint responses.

KW - BRCA1

KW - Cdc2

KW - Cdc25C

KW - Chk1

KW - ERK1/2 and Wee1

UR - http://www.scopus.com/inward/record.url?scp=18844376884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18844376884&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1208492

DO - 10.1038/sj.onc.1208492

M3 - Article

C2 - 15735702

AN - SCOPUS:18844376884

VL - 24

SP - 3285

EP - 3296

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 20

ER -